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Previously, the adenovirus proteinase (AVP) had been shown to be stimulated by an 11-amino-acid cofactor pVIc; the
crystal structure of an AVP–pVIc complex formed in vitro reveals a disulfide bond between AVP and pVIc. However, that
disulfide bond was recently shown not to be required for maximal stimulation of enzyme activity by pVIc in vitro. Is the
disulfide bond physiologically relevant or is it an artifact that arose in the crystallization of the complex? Here we show that
a disulfide bond between AVP and pVIc is physiologically relevant, because in the virus particle AVP is linked to pVIc via a
disulfide bond. This is also the first experimental proof that AVP interacts in vivo with one of its cofactors, all of which wereINTRODUCTION
The human adenovirus serotype 2 proteinase (AVP) is
required for the synthesis of infectious virus (Weber,
1976). Late in infection, young virions are formed in which
6 of the 12 major virion proteins are precursor proteins.
In the young virion, about 70 AVP molecules become
activated (Brown et al., 1996), and they carry out over
3200 cleavages of multiple copies of the 6 precursor
proteins, thereby rendering a virus particle infectious
(Rancourt et al., 1995). A temperature-sensitive mutant of
adenovirus was shown to lack proteinase activity at the
nonpermissive temperature (Weber, 1976). The mutation
was mapped to the L3 23K gene (Yeh-Kai et al., 1983).
The L3 23K gene was cloned and expressed in Esche-
richia coli (Anderson, 1993; Mangel et al., 1993) or bac-
ulovirus-infected insect cells (Webster et al., 1993) and
the resultant 204-amino-acid protein AVP was purified
(Mangel et al., 1993; Webster et al., 1993).
In vitro, the recombinant form of AVP is relatively in-
active (Baniecki et al., 2001; Mangel et al., 1993; McGrath
et al., 2001a; Webster et al., 1993). Eventually, cofactors
were discovered. One cofactor is the 11-amino-acid pep-
tide, GVQSLKRRRCF, originating from the C-terminus of
the precursor to protein VI, pVIc. The other cofactor is the
viral DNA (Mangel et al., 1993). In vitro, the two viral
cofactors increase the specificity constant, k cat/Km, for
substrate hydrolysis (McGrath et al., 2001a). If the rela-
tive k cat/Km for AVP alone is 1, for an AVP–pVIc complex
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234it is 1130, for an AVP–DNA complex it is 110, and for an
AVP–pVIc–DNA complex it is 34,100.
The crystal structure of the AVP–pVIc complex reveals
where and how pVIc binds to AVP (Ding et al., 1996).
Cys104 of AVP forms a disulfide bond with Cys10 of
pVIc; both Cys104 and Cys10 are conserved among
adenovirus serotypes. The active-site nucleophile, the
Cys122–His54 ion pair, is located in a groove on the
surface of the enzyme. Surprisingly, pVIc, which greatly
increases the k cat/Km for substrate hydrolysis by AVP,
binds quite far from the active-site nucleophile; the pVIc
Cys10 residue is 32 Å away from Cys122. The interac-
tion between pVIc and AVP is extensive. There are 24
non--strand hydrogen bonds and 6 -strand hydrogen
bonds, as well as the covalent bond.
The disulfide bond between pVIc and AVP is not re-
quired for maximal stimulation of AVP by pVIc (McGrath
et al., 2001b). At a concentration of pVIc fivefold greater
than its equilibrium dissociation constant, K d, for AVP, the
half-time for formation of a disulfide bond with AVP is 29
min. Yet, when the same concentration of pVIc is added
to a solution of AVP and substrate, there is a lag of only
3 min before the maximal rate of substrate hydrolysis is
reached. Because upon addition of pVIc to AVP and
substrate, the maximal rate of substrate hydrolysis is
reached before a disulfide bond can form, formation of
the disulfide bond is therefore not necessary for maximal
stimulation of AVP by pVIc. This then raises the question
as to whether the disulfide bond observed in the crystal
structure of AVP–pVIc (Ding et al., 1996) is physiologically
relevant or is an artifact that arose by the high concen-discovered and characterized in vitro. A rationale as to wh
pVIc forms in the virus particle is presented. © 2002 Elsevie
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If the disulfide bond is physiologically relevant, then
there should be covalently linked AVP–pVIc complexes in
the virus particle. To determine directly whether a disul-
fide bond forms between AVP and pVIc in vivo, in the
virus particle, a series of Western blots was run under
reducing and nonreducing conditions using a new
method to enhance retention of small peptides on mem-
branes during immunoblotting. The data indicated that in
the virus particle, there is an AVP–pVIc complex linked by
a disulfide bond. This conclusion is also the first evi-
dence that AVP interacts with a cofactor in vivo; hereto-
fore, all the experiments with AVP cofactors were done in
vitro. Finally, we present a rationale for the involvement
of disulfide bond formation in the activation of AVP in the
virus particle, given that the bond is not necessary for
maximal stimulation of enzyme activity by pVIc.
RESULTS
Demonstration that pVIc forms a disulfide bond with
AVP in vitro
Formation of a disulfide bond between AVP and pVIc in
vitro in the presence or absence of Ad2 DNA was shown
by a direct method, Western blotting (Towbin et al., 1979),
using a new protocol designed to increase retention of
peptides on membranes. AVP–pVIc complexes were
formed in the presence of 17 g/ml Ad2 DNA by incu-
bating 2 M AVP with 2.5 M pVIc, a concentration of
pVIc 28-fold higher than its K d for AVP in the presence of
DNA (Baniecki et al., 2001). AVP–pVIc complexes were
formed in the absence of Ad2 DNA by incubating 7 M
AVP with 50 M pVIc, a concentration of pVIc 12-fold
higher than its K d in the absence of DNA. Then, both
nonreduced and reduced SDS–polyacrylamide gels
were run. For the nonreduced gel, -mercaptoethanol
was omitted from the SDS–PAGE sample buffer. After
SDS–PAGE, the proteins in the gels were transferred to
bovine serum albumin (BSA)-treated membranes, fixed
with glutaraldehyde, and immunoblotted using affinity-
purified polyclonal antibodies raised against pVIc. pVIc,
which has two primary amines, should cross-link to BSA.
The data are shown in the nonreduced and reduced
Western blots in Fig. 1. In the nonreduced blot, a high-
molecular-weight complex with pVIc is observed in lane
1 where AVP was incubated with pVIc and DNA and in
lane 3 where AVP was incubated with pVIc. That these
high-molecular-weight complexes are AVP–pVIc com-
plexes held together by disulfide bonds is shown by the
experiment in the reduced blot. In lane 3 of the reduced
blot, the AVP–pVIc complex that migrated as a high-
molecular-weight complex in lane 3 in the nonreduced
FIG. 1. Demonstration of the formation of a disulfide bond formed in vitro between pVIc and AVP, in the presence or absence of Ad2 DNA, as
assayed by immunoblotting. Samples for the nonreduced gel contained in lane 1 (0.015 g AVP–pVIc complexes formed by incubating overnight 2
M AVP with 2.5 M pVIc and 17 g/ml Ad2 DNA, as described under Materials and Methods), in lane 2 (0.03 g AVP), and in lane 3 (0.03 g
AVP–pVIc complexes formed by incubating overnight 7 M AVP with 50 M pVIc, as described under Materials and Methods). Samples for the
reduced gel contained in lane 1 (0.03 g AVP), lane 2 (0.03 g pVIc), and lane 3 (0.03 g AVP–pVIc complexes formed by incubating overnight 7 M
AVP and 50 M pVIc, as described under Materials and Methods). After SDS–PAGE, the proteins in the gels were transferred to BSA-containing
Immobilon membranes, fixed with glutaraldehyde, and immunoblotted with anti-pVIc antibody.
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blot now migrates as pVIc. pVIc alone is in lane 2 in the
reduced blot.
The blots showed that the anti-pVIc antibody was
specific for pVIc. The data in lane 2 of the nonreduced
blot and in lane 1 of the reduced blot showed that the
anti-pVIc antibody did not react with AVP. In lanes 2 and
3 of the reduced blot the anti-pVIc antibody reacted with
a band that migrated in a position where pVIc should be,
i.e., near the bottom of the membrane. In the nonreduced
blot, the band of pVIc is darker in lane 3 than in lane 1.
This is because lane 3 has sixfold more pVIc than lane 1.
These data clearly show that the method can be used to
detect a disulfide bond formed in vitro between pVIc and
AVP and that a disulfide bond was able to form in vitro
between pVIc and AVP in the presence or absence of
Ad2 DNA.
Kinetics of formation of a disulfide formed in vitro
between pVIc and AVP
The rate of formation of a disulfide bond in vitro is
relatively slow, much slower than the rate of formation of
a reversible AVP–pVIc complex (McGrath et al., 2001b).
AVP was incubated with pVIc in the absence or presence
of Ad2 DNA and, after varying time intervals, aliquots of
the reactions were diluted 15-fold in nonreducing SDS–
PAGE buffer. After SDS–PAGE, the proteins in the gels
were transferred to BSA-treated Immobilon membranes,
fixed with glutaraldehyde, and immunoblotted with anti-
pVIc antibody. The results (Fig. 2A in the absence of Ad2
DNA and Fig. 2B in the presence of Ad2 DNA) showed
that the amount of disulfide-bonded complex increased
as a function of time. Very little AVP had formed a disul-
fide bond with pVIc within 1 h; the majority of disulfide-
bonded complex required more than 6 h to form, in the
absence or presence of Ad2 DNA. In this method, any
pVIc that migrates with AVP is considered to have formed
a disulfide bond with AVP.
Demonstration that in vivo, in the virus particle, pVIc
formed a disulfide bond with AVP
If a disulfide bond between pVIc and AVP is not nec-
essary for maximal stimulation of enzyme activity
(McGrath et al., 2001b), then does a disulfide bond form
in vivo in the virus particle? To answer this question,
disrupted wild-type Ad2 virions, prepared by incubation
at 56°C for 20 min in 10 mM HEPES (pH 8.0) and 5 mM
iodoacetamide, were placed in SDS–PAGE sample buffer
in the absence or presence of 5% -mercaptoethanol
and then sonicated for 5 min before being heated in a
boiling water bath for 3 min. After SDS–PAGE, the pro-
teins in the gel were transferred to BSA-treated mem-
branes, cross-linked by glutaraldehyde, and immunoblot-
ted. The data are shown in Fig. 3. In lane 1, the nonre-
duced gel, there are bands immunoreactive to anti-pVIc
antibody at the AVP–pVIc position and at the pVIc posi-
tion. In lane 2, the reduced gel, there is a band immu-
noreactive to anti-pVIc antibody only at the pVIc position.
A control experiment was performed to confirm that
the immunoreactive band at the AVP–pVIc position in
lane 1 of the nonreduced gel in Fig. 3 that reacted with
anti-pVIc antibody is indeed an AVP–pVIc complex in the
virus. This is shown in the reduced blot in Fig. 3, lane 3,
where the band illuminated by anti-AVP antibody mi-
grated to the same position as the band in lane 1 that
was illuminated by anti-pVIc antibody. These data clearly
showed that pVIc had formed a disulfide bond with AVP
in vivo, in the virus particle.
FIG. 2. Kinetics of disulfide bond formation in vitro between pVIc and AVP in the absence (A) or in the presence (B) of Ad2 DNA, as assayed by
immunoblotting. (A) Reactions in the absence of DNA contained 7 M AVP and 50 M pVIc and were incubated for the indicated periods of time after
which aliquots were diluted 15-fold for nonreducing SDS–PAGE. (B) Reactions in the presence of DNA contained 17 g Ad2 DNA, 2 M AVP, and 2.5
M pVIc and were incubated for the indicated periods of time after which aliquots were diluted 15-fold for nonreducing SDS–PAGE. After SDS–PAGE,
the proteins in the gels were transferred to BSA-treated Immobilon membranes, fixed with glutaraldehyde, and immunoblotted with anti-pVIc antibody.
pVIc signifies pVIc alone. The times, 0–360, are in minutes. O/N signifies overnight.
236 MCGRATH, AHERNE, AND MANGEL
DISCUSSION
The experiments described here show conclusively
that in the adenovirus particle, a disulfide bond is formed
between AVP and pVIc. This is the first experimental
proof that AVP interacts in vivo with one of its cofactors,
all of which were discovered and characterized in vitro
(Mangel et al., 1993; Webster et al., 1993). Our model for
the activation of AVP in the immature virion postulates
that AVP bound to the viral DNA encounters pVI and cuts
out pVIc, which then binds to the enzyme that cut it out
(McGrath et al., 2001a). The equilibrium dissociation con-
stant, K d, for the reversible binding of pVIc to AVP is 4.4
M (Baniecki et al., 2001). In the presence of 12-mer
ss-DNA, the K d decreases to 0.09 M. Apparently, the
binding of DNA to AVP makes the pVIc binding site on
AVP more accessible. Eventually a covalent bond is
formed between AVP and pVIc. Even though pVIc is a
basic protein that binds to DNA with an apparent K d of
693 M (McGrath et al., 2001a), a conclusion from the
experiments in Figs. 1 and 2 is that pVIc can bind and
form a disulfide bond with AVP in the presence of Ad2
DNA.
pVIc reversibly bound to AVP can stimulate enzyme
activity (Baniecki et al., 2001; McGrath et al., 2001b).
Furthermore, the maximal rate of substrate hydrolysis by
the reversible AVP–pVIc complex is equal to the rate of
substrate hydrolysis of disulfide-linked AVP–pVIc com-
plexes (McGrath and Mangel, unpublished results).
Upon addition of monomeric pVIc to AVP, the maximal
rate of substrate hydrolysis was achieved within 3 min; in
the presence of DNA, the maximal rate of substrate
hydrolysis was reached in less than 1 min.
There have been conflicting reports as to whether
Cys10 in pVIc is essential for the reversible binding of
pVIc to AVP. Using mass spectrometry as an assay for
binding, the pVIc mutant C10S (GVQSLKRRRSF) was
shown not to bind to AVP (Cabrita et al., 1997). However,
the concentrations of the C10S mutant used, up to 40
M, are too low to see binding. The C10S mutant does
bind to AVP and upon binding stimulates enzyme activity;
the K d for binding is quite high, greater than 400 M
(McGrath et al., 2001b). Ruzindana-Umunyana et al.
(2000) were able to titrate AVP with the C10S mutant and
concluded that formation of a disulfide bond between
pVIc and AVP is not necessary for pVIc to stimulate
enzyme activity. However, analysis of their titration data
indicated the K d is less than 2 M (our inference). Al-
though we obtained a K d much greater than 400 M for
the binding of the C10S mutant to AVP, in the presence
of 12-mer ss-DNA, the K d dropped to 7.6 M (McGrath et
al., 2001b). Thus, it appears as if their assays contained
polyanion.
Before determining by Western blot analysis (Towbin
et al., 1979) whether a disulfide bond between AVP and
FIG. 3. Formation of a disulfide bond between pVIc and AVP in adenovirus virions. Disrupted wild-type Ad2 virions, 1010, prepared by incubation
at 56°C for 20 min in 10 mM HEPES (pH 8.0) and 5 mM iodoacetamide, were placed in SDS–PAGE sample buffer plus or minus 5% -mercaptoethanol
and then sonicated for 5 min prior to being put in a boiling water bath for 3 min. After SDS–PAGE, the proteins in the gels were transferred to a treated
Immobilon membrane, fixed with glutaraldehyde, and immunoblotted with either anti-pVIc antibody or anti-AVP antibody, as indicated.
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pVIc formed in vitro or in the virus particle in vivo, certain
aspects of the Western blotting procedure had to be
investigated. pVIc is a small peptide (MW 1350) and
although it can be fractionated as a diffuse band upon
SDS–PAGE and be transferred efficiently from gel to
membrane, it is not efficiently retained on the membrane
support during the long incubations with antibodies and
washes (Tovey and Baldo, 1989). To enhance the reten-
tion of pVIc on a membrane, the membrane was pre-
treated with BSA, proteins were electrophoretically trans-
ferred to the membrane after SDS–PAGE, and then the
transferred proteins were cross-linked by glutaraldehyde
to the BSA bound to the membrane. The results indicated
an approximate 2000-fold increase in the retention of
pVIc on the membrane (McGrath and Mangel, unpub-
lished results).
This method of Western blotting was validated when it
was used to demonstrate the presence of a disulfide
bond in AVP–pVIc complexes formed in vitro (Fig. 1). The
pVIc in the AVP–pVIc complexes could be clearly seen
on the blot from the nonreduced gel but not on the blot
from the reduced gel. The 7:1 molar ratio of pVIc to AVP
used in the experiment in the absence of DNA was
similar to that found in wild-type Ad2 virions (Brown et al.,
1996; Oosterom-Dragon and Anderson, 1983).
This new method of Western blotting was used to
measure the kinetics of disulfide bond formation in vitro
between AVP and pVIc in the absence or presence of
Ad2 DNA. Previously, this had been done in the absence
of DNA by an indirect method wherein enzyme activity
that remained after dilution below the K d for AVP and
pVIc signified formation of a disulfide bond (McGrath et
al., 2001b). The results of the direct experiments in Fig. 2
confirmed that the rate of disulfide bond formation was
relatively slow; the majority of AVP appeared not to have
formed a disulfide bond with pVIc within 6 h. These
results then reinforce the conclusion that formation of a
disulfide bond between AVP and pVIc is not necessary
for maximal stimulation of AVP by pVIc. Since upon ad-
dition of monomeric pVIc to AVP the maximal rate of
substrate hydrolysis was achieved within 3 min
(McGrath et al., 2001b), the results of the direct experi-
ment in Fig. 2 reinforce the conclusion that formation of
a disulfide bond between AVP and pVIc is not necessary
for the enzyme to be maximally stimulated by pVIc.
This method of Western blotting was then used to
show that in vivo, in the virus particle, pVIc had formed a
disulfide bond with AVP (Fig. 3). In the blot of the nonre-
duced gel, a band illuminated by anti-pVIc antibody
comigrated with AVP–pVIc. That band was absent in the
blot of the reduced gel. During disruption of the virus
before SDS–PAGE, 5 mM iodoacetamide was present.
This ensured that all free thiols would become alkylated,
and thus, no new disulfide bonds could form in vitro.
Greber et al. (1996) have also fractionated virion pro-
teins under reducing and nonreducing conditions. Their
Western blot was probed with an antibody directed
against AVP, whereas we used an antibody directed
against pVIc. To see if pVIc (MW 1350) binds to AVP (MW
23,000) using an anti-AVP antibody, the gel would have to
resolve two proteins with molecular weights of 23,000
and 24,350. This is why the authors conclude that their
results are consistent with the presence of an interchain
disulfide that connects AVP to pVIc. Furthermore, there
are several low-molecular-weight peptides present in
adenovirus virions; using an antibody directed against
AVP would not differentiate between those small pep-
tides and pVIc. The results presented here are more
definitive, because an anti-pVIc antibody is used; in this
case the gel has only to resolve two proteins with mo-
lecular weights of 1350 and 24,350 (Figs. 1–3).
The data in Fig. 3 are consistent with the conclusion
reached via indirect evidence that there are about 70
proteinase molecules per virion (Brown et al., 1996).
There are 340 molecules of pVI per virion (van Oosterom
and Burnett, 1985). The immunoblots in Fig. 3 indicated
that in the virus apparently all the pVI had been pro-
cessed; there was no detectable pVI, only pVIc. The pVIc
band at the bottom of the blot in lane 1 in Fig. 3 is much
more intense than the band associated with AVP–pVIc
complexes. This quite possibly reflects a ratio of pVIc to
AVP predicted to be 340:70 (Brown et al., 1996; Oost-
erom-Dragon and Anderson, 1983). At the very least, it
indicates that there are many more molecules of pVIc per
virion than AVP.
If the formation of a disulfide bond between pVIc and
AVP is not necessary for maximal stimulation of enzyme
activity by pVIc, why does this bond form in vivo, in the
virus particle? Perhaps the covalent attachment of pVIc
to AVP is important to enzyme activity, but in an indirect
way. Given the relatively low concentration of pVI and
AVP in the virion, reversible binding of pVIc to AVP might
not lead to activation of all the molecules of AVP all the
time. This might prevent all the precursor proteins from
being processed. By forming a covalent bond, an AVP
molecule becomes irreversibly activated; i.e., pVIc can-
not reversibly dissociate due to its low concentration. As
to how the covalent bond is formed initially, perhaps AVP,
bound to the viral DNA, encounters pVI and cleaves out
pVIc, which in turn binds to the enzyme that cut it out.
The pVIc would bind to the AVP bound to the DNA
because the equilibrium dissociation constant of AVP for
pVIc is 4.4 M in the absence of DNA and 90 nM in the
presence of DNA (Baniecki et al., 2001).
MATERIALS AND METHODS
Materials
Recombinant AVP was purified as previously de-
scribed (Mangel et al., 1996). pVIc was purchased from
Research Genetics (Huntsville, AL). BSA, Ad2 DNA, and
Ellman’s reagent, 5,5-dithio-bis(2-nitrobenzoate) or DTNB
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were purchased from Sigma Chemical Co. (St. Louis, MO).
Glutaraldehyde was purchased from Kodak (Rochester,
NY). Polyclonal antibodies elicited by pVIc or AVP were
purchased from Cocalico Biologicals Inc. (Reamstown, PA).
Triton X-100, SDS, BCIP/NBT Color Development Solution,
and blotting grade affinity-purified goat anti-rabbit IgG
(HL) alkaline phosphatase conjugate human IgG ad-
sorbed were purchased from Bio-Rad Laboratories (Her-
cules, CA). Polyacrylamide gel electrophoresis and electro-
phoretic transfer materials were purchased from Pharma-
cia LKB Technologies (Piscataway, NJ). Immobilon P
transfer membrane (LeGendre, 1990) was purchased from
Millipore (Boston, MA).
Protein concentration
Protein concentration was determined by the BCA
protein assay (Pierce, Rockford, IL). For AVP, the concen-
tration was also determined by absorbance using a cal-
culated molar extinction coefficient at 280 nm of 26,510
(Gill and von Hippel, 1989). The concentration of pVIc
was determined by titration of its cysteine with Ellman’s
reagent; results were confirmed by quantitative amino
acid analysis. The titration was done by adding 10 l of
stock pVIc solution to 0.99 ml of 0.33 mM DTNB in
Ellman’s buffer, which contained 0.1 M NaH2PO4 (pH 7.3)
and 1 mM EDTA. The absorbance at 412 nm was read.
Moles of thiolate anion were calculated using a molar
extinction coefficient for thionitrobenzoate at 412 nm of
14,150 (Riddles et al., 1979).
Formation of disulfide-linked AVP–pVIc complexes
Complexes of AVP and pVIc (AVP–pVIc) were formed
by incubating 7 M AVP with 50 M pVIc in 10 mM
Tris–HCl (pH 8.0) for varying periods of time at 25°C.
Complexes of AVP and pVIc were formed in the presence
of Ad2 DNA by incubating 2 M AVP with 2.5 M pVIc in
the presence of 17 g/ml Ad2 DNA in 10 mM Tris–HCl
(pH 8.0) for varying periods of time at 25°C. The reac-
tions were diluted 15-fold with buffer prior to SDS–PAGE.
Antibodies
The anti-pVIc antibody, elicited in rabbits as a BSA
conjugate, was affinity purified using a keyhole limpet
hemocyanin–pVIc peptide conjugate coupled to Amino-
Link Gel from Pierce. The pVIc peptide conjugate was
made using the Imject maleimide activated keyhole lim-
pet hemocyanin from Pierce. Conjugation and coupling
of the conjugate to AminoLink Gel were performed ac-
cording to the manufacturer’s instructions. Affinity-puri-
fied pVIc antibody was stored at 20°C.
Polyclonal antibodies elicited against purified AVP
were raised in rabbits and the sera were diluted 1:200 in
blocking buffer prior to use.
SDS–polyacrylamide gel electrophoresis and transfer
of proteins to membranes
SDS–polyacrylamide electrophoresis was carried out
in 8–25% gradient gels using the Pharmacia PhastSys-
tem according to the manufacturer’s instructions. Sample
buffer contained 0.01 M Tris–HCl (pH 8.0), 0.001 M EDTA,
2.5% (w/v) SDS, and 0.01% (w/v) bromophenol blue; for
reduced gels, 5% (v/v) -mercaptoethanol was also
present in the sample buffer. After electrophoresis, the
gel was soaked for 10 min in 0.05 M HEPES (pH 7.5)
containing 20% (v/v) glycerol. Protein transfer from gel to
Immobilon-P membranes was done with the semidry
transfer apparatus from Pharmacia using the times and
currents recommended by the manufacturer.
Preparation of membranes for transfer
The membranes were prepared for transfer by incu-
bating them for 30 min in 0.01 M TAPS (pH 8.6) containing
0.025% (w/v) BSA. Just prior to being placed under the
gel, the membrane was dipped in anode transfer buffer,
0.01 M TAPS (pH 8.6) with 35% (v/v) methanol. The gel
was cut away from its Mylar backing with a taut wire. The
semidry electrophoretic transfer method involved the use
of filter papers soaked in transfer buffers placed over
and under the gel/membrane sandwich. The anode
buffer was 0.01 M TAPS (pH 8.6) containing 35% (v/v)
methanol. The cathode buffer was 0.01 M TAPS (pH 8.6)
containing 0.1% (w/v) SDS and 20% (v/v) methanol. Trans-
fer took place at 20 V (25 mA) for 5 Vh at 15°C. Afterward,
the membrane was placed in 0.01 M TAPS (pH 8.6)
containing freshly prepared 0.25% (v/v) glutaraldehyde
and incubated for 15 min at room temperature. Glutaral-
dehyde cross-links free primary amines, i.e., the primary
amine at the N-terminus of proteins and the -amino
group of lysine residues. Fixation should not be done in
buffers with primary amines such as Tris–HCl. After fix-
ation, the glutaraldehyde was quenched by incubating
the membrane in 0.2 M Tris–HCl (pH 7.5) for 5 min. The
membrane was rinsed with distilled water and incubated
in blocking buffer, 0.1 M Tris–HCl (pH 7.4) containing 0.9%
(w/v) NaCl and 3% (w/v) BSA, for at least 1 h.
Antibody binding and development of the blot
For antibody binding, the membrane was rinsed with
distilled water and incubated for 2–16 h with a 1:200
dilution in blocking buffer of primary antibody, either
anti-AVP or anti-pVIc. This and all subsequent incuba-
tions were performed at room temperature in solutions
that were gently rocked back and forth, to facilitate dif-
fusion. The incubation was followed by four 10-min
washes with 0.01 M Tris–HCl (pH 7.4) containing 0.9%
(w/v) NaCl, 0.1% (w/v) BSA, 0.1% (v/v) Triton X-100, and
0.05% (w/v) SDS (TBSXS) and a 5-min wash in blocking
buffer. The membrane was then incubated for 1–2 h with
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the secondary antibody (goat anti-rabbit IgG–alkaline
phosphatase conjugate) solution (1:1500 dilution in
blocking buffer). After four more 10-min washes with
TBSXS, the membrane was washed for 10 min with PBS
and then developed using the NBT/BCIP methodology
(Bio-Rad Laboratories). After color development, the
membrane was rinsed with distilled water, incubated in
0.05 M sodium acetate (pH 5.0) containing 0.025 M EDTA
for 30 min, rinsed with water, and dried.
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